| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we mainly focused on secondary carnitine deficiency due to pivalete-conjugated drugs. We retrospectively investigated the age, clinical manifestations, PCA administration period, and background of 25 patients who showed a decrease in free carnitine (C0, nmol/mL) concomitant with an increase in pivaloyl carnitine (C5) on acylcarnitine analysis with tandem mass spectrometry. Carnitine deficiency resulting from PCA treatment was most frequently observed in 1-year-old infants. Most patients manifested acute encephalopathy and/or hypoglycemia. Some patients developed carnitine deficiency after PCA administration for <14 days. We reported two patients who showed increased value of C5 by sivelestat sodium.
In the present study, we developed an in vitro probe assay for analyzing intra-and extra-cellular ACs.
|
